Economic Evaluation of Screening Strategies Combined with HPV Vaccination of Preadolescent Girls for the Prevention of Cervical Cancer in Vientiane, Lao PDR

Phetsavanh Chanthavilay1,2*, Daniel Reinharz2,3☯, Mayfong Mayxay1,4,5☯, Keokedthong Phongsavan6☯, Donald E. Marsden5☯, Lynne Moore2☯, Lisa J. White7,8☯

1 Faculty of Postgraduate Studies, University of Health Sciences, Vientiane, Lao PDR, 2 Department of Social and Preventive Medicine, Faculty of Medicine, Laval University, Quebec, Canada, 3 Institut de la Francophonie pour la Médecine tropicale, Vientiane, Lao PDR, 4 Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR, 5 Centre for Tropical Medicine and Global Health, Churchill Hospital, University of Oxford, Oxford, United Kingdom, 6 Gynecologic Oncology Unit, Sethathirath Hospital, Vientiane, Lao PDR, 7 Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, 8 Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

* These authors contributed equally to this work.

Citation: Chanthavilay P, Reinharz D, Mayxay M, Phongsavan K, Marsden DE, Moore L, et al. (2016) Economic Evaluation of Screening Strategies Combined with HPV Vaccination of Preadolescent Girls for the Prevention of Cervical Cancer in Vientiane, Lao PDR. PLoS ONE 11(9): e0162915. doi:10.1371/journal.pone.0162915

Abstract

Background
Several approaches to reduce the incidence of invasive cervical cancers exist. The approach adopted should take into account contextual factors that influence the cost-effectiveness of the available options.

Objective
To determine the cost-effectiveness of screening strategies combined with a vaccination program for 10-year old girls for cervical cancer prevention in Vientiane, Lao PDR.

Methods
A population-based dynamic compartment model was constructed. The interventions consisted of a 10-year old girl vaccination program only, or this program combined with screening strategies, i.e., visual inspection with acetic acid (VIA), cytology-based screening, rapid human papillomavirus (HPV) DNA testing, or combined VIA and cytology testing. Simulations were run over 100 years. In base-case scenario analyses, we assumed a 70% vaccination coverage with lifelong protection and a 50% screening coverage. The outcome of interest was the incremental cost per Disability-Adjusted Life Year (DALY) averted.

Results
In base-case scenarios, compared to the next best strategy, the model predicted that VIA screening of women aged 30–65 years old every three years, combined with vaccination,
was the most attractive option, costing 2,544 international dollars (I$) per DALY averted. Meanwhile, rapid HPV DNA testing was predicted to be more attractive than cytology-based screening or its combination with VIA. Among cytology-based screening options, combined VIA with conventional cytology testing was predicted to be the most attractive option. Multi-way sensitivity analyses did not change the results. Compared to rapid HPV DNA testing, VIA had a probability of cost-effectiveness of 73%. Compared to the vaccination only option, the probability that a program consisting of screening women every five years would be cost-effective was around 60% and 80% if the willingness-to-pay threshold is fixed at one and three GDP per capita, respectively.

**Conclusions**

A VIA screening program in addition to a girl vaccination program was predicted to be the most attractive option in the health care context of Lao PDR. When compared with other screening methods, VIA was the primary recommended method for combination with vaccination in Lao PDR.

**Introduction**

While there are few accurate data regarding the incidence or mortality of cervical cancer (or any cancer, in fact) in the Lao PDR, it constitutes a major public health burden with a high rate of morbidity and mortality in both reproductive age and older women [1]. Cervical cancer is the third most common cancer in Lao women and the third leading cause of cancer deaths [1]. The Lao PDR is one of 72 countries eligible for support from the Global Alliance for Vaccines and Immunization (GAVI), for HPV vaccination programs. A pilot project of an HPV vaccination program targeting fifth grade girls was launched in Vientiane capital and Vientiane province in October 2013. Vaccination can be expected to reduce the number of cervical cancers by about 70–75%, by conferring protection against HPV types 16 and 18 related cancers. Moreover, only once high levels of coverage of the female population are achieved, after a few decades of girl vaccination, might unvaccinated women benefit from herd immunity [2]. Therefore large scale community screening programs are needed to significantly affect the incidence and mortality of the disease among the population as a whole [3]. A screening program that targets women who are not covered by the usual vaccination program might be an effective complement to the vaccination of schoolgirls.

Despite the availability of cytology screening facilities in the country, at least in Vientiane Capital, only 5.2% of women aged 18–69 years in urban areas and 1.4% in rural areas have ever had cytological screening, either as part of a community screening program, or opportunistically when visiting a health care facility for some other reason [1]. Opportunistic screening is less effective than organized programs [4], and there are a range of screening strategies which show different levels of efficacy in terms of sensitivity and specificity. Several screening approaches may be implemented. Visual inspection with acetic acid (VIA) and cytology show low reproducibility. Cytology requires expertise, a healthcare infrastructure and resources, and it has a low sensitivity and high cost compared to VIA [5]. Meanwhile, VIA has a low specificity and a low positive predictive value (PPV), leading to unnecessary treatment [6]. In contrast, a rapid HPV DNA testing approach provides simple, accurate and reproducible results [7, 8]. However, its use in developing countries is limited by its high cost and due to the fact that
HPV DNA testing only detects HPV infection, but not precursors of cancer, so that there is a need for follow up of positive results [9].

Which screening strategy should be implemented in a developing country with scarce resources devoted to health care like Lao PDR? To answer this crucial question for the country, we need to consider not only the demonstrated effectiveness of a screening program, but also its cost. Health policy decision makers in Lao PDR are lacking key information to decide about the relative value of the diverse screening programs that might be implemented in the country.

The goal of this study was to determine, using mathematical modelling, the cost-effectiveness of various options regarding cervical cancer screening strategies along with an HPV vaccination program for girls in Vientiane, the capital of Lao PDR.

Materials and Methods

The outcome of interest was incremental cost-effectiveness (C/E) ratios (ICERs). The C/E denominator consisted of 1) the reduction in the incidence of cervical cancers and 2) DALYs averted related to all cervical cancer cases. The numerator consisted of the direct cost of the various options compared, from a public health care system perspective. This economic evaluation study complied with the recommendations of WHO for cost-effectiveness analyses [10].

Virtual population

The initial virtual population (at year 1) consisted of the entire population of women with characteristics similar to the population of Vientiane capital in terms of age distribution [11] and estimated age-specific incidence rates of cervical cancer in 2014 [1]. The Vientiane capital population was used in the model instead of the whole country due to the fact that the population of the country is predominantly rural [12], and the ethnic mix of the population [13] is likely to be very different in each of the provinces; subsequently the vaccination uptake might be different.

Model structure and parameters of natural history

The details of the model structure are described in the S1 Appendix. Briefly, a compartmental dynamic population-based model was created to represent the natural history of cervical cancer both in females and males. Susceptible girls and boys were considered to be at risk of being infected based on estimated infection rates between partners. For both males and females, the model considered if the HPV genotype was a 16, 18 or other high-risk types, or if it was of low-risk types.

For females, the model considered that an infection with HPV might recover with natural immunity, while remaining susceptible to infection with other HPV types. HPV infection might persist or progress into a cervical intraepithelial neoplasia (low-grade CIN or high-grade CIN). A low-grade CIN might recover with immunity or regress to an infection state, or progress into a high-grade CIN. A high-grade CIN might recover with immunity or regress to an infection state or low-grade CIN, or might progress into an invasive cervical cancer (local, regional or distant, respectively). Women diagnosed with a high-grade CIN are treated. Women with invasive cervical cancer might be symptomatically detected. Diagnosed cancer cases are treated, with a probability of recovery, treatment failure or death (Fig 1).

For the screening model, true high-grade cervical intraepithelial neoplasia (CIN) cases diagnosed at a cytology examination or rapid HPV DNA testing receive a loop electrosurgical excision procedure (LEEP) or hysterectomy treatment. When VIA is used, a see-and-treat approach is adopted. True positive and false positive high-grade CIN cases receive cryotherapy treatment. The detail of screening procedure is provided in the S1 Appendix. Cured cases
regress to a recovery state with type-specific natural immunity. Unscreened or undetected cases, or treatment failure follow the natural history of HPV infection, which may lead to cervical cancer (Fig 1).

For males, only the susceptibility, infection and recovery states were considered. Vaccinated people remained susceptible for non-vaccine HPV types (Fig 1).

The progression and regression rates from one state to another one were based on the literature [14] as described in Table 1. However, we calibrated infection rates and cancer stage-remission rates. The sensitivity and specificity of screening and diagnostic tests and remission
| Parameters | Baseline values* | Source |
|------------|-----------------|--------|
| **Progression** | | |
| Healthy to infection † (-20 and +40%) | | |
| HPV-16 | 0.000175–0.003148 (0.0001426–0.00761) | Calibrated |
| HPV-18 | 0.0004–0.000789 (0.000102–0.00168) | |
| Other HR HPV | 0.000206–0.004038 (0.0001703–0.00911) | |
| LR HPV | 0.000958–0.018412 (0.00069–0.0537) | |
| HPV DNA to CIN1‡ | | [14] |
| HR-16 HPV | 0.005194–0.00901 | |
| HR-18 HPV | 0.002793–0.004845 | |
| HR-other HPV | 0.007693–0.013345 | |
| LR-HPV | 0.002397–0.001222 | |
| Proportion (%) of women who transition directly from HPV DNA to CIN2,3 | | |
| HR-16 HPV | 0.64 | |
| HR-18 HPV | 0.975 | |
| HR-other HPV | 0.966 | |
| LR-HPV | 0.98 | |
| CIN 1 to CIN 2,3 ‡ | | |
| HR-16 HPV | 0.00951–0.012363 | |
| HR-18 HPV | 0.0051–0.00663 | |
| HR-other HPV | 0.00747–0.009711 | |
| LR-HPV | 0.000149–0.000222 | |
| CIN 2,3 to local cancer | | |
| HR-16 HPV | 0.000151–0.000906 | |
| HR-18 HPV | 0.000264–0.001584 | |
| HR-other HPV | 0.000199–0.01194 | |
| Local to regional invasive cancer | 0.0200 | |
| Regional to distant invasive cancer | 0.0250 | |
| **Regression** | | |
| HPV DNA to Normal | | |
| HR-16 HPV | 0.09089 | |
| HR-18 HPV | 0.09089 | |
| HR-other HPV | 0.09272 | |
| LR-HPV | 0.09699 | |
| CIN 1 to normal ‡‡ | | |
| HR-16 HPV | 0.03782 | |
| HR-18 HPV | 0.03782 | |
| HR-other HPV | 0.04575 | |
| LR-HPV | 0.01708 | |
| CIN 2,3 to Normal §§ | | |
| HR-16 HPV | 0.000798–0.000455 | |
| HR-18 HPV | 0.003556–0.011938 | |
| HR-other HPV | 0.002926–0.009823 | |
| LR-HPV | 0.001904–0.006392 | |
| Other | | |
| Immunity (%) (HR-HPV types only) ¶¶ | | |
| HR-16 HPV | 0.66 | |
| HR-18 HPV | 0.86 | |
| HR-other HPV | 0.59 | |
| Annual probability of symptom detection # | | |
| Local invasive cancer | 0.33 | |
| Regional invasive cancer | 0.60 | |
| Distant cancer | 0.9 | |
| Proportion of cancer patient receiving the treatment | | |
| Local cancer | 100% | Assumption |
| Regional cancer | 87% | |
| Distant cancer | 78% | |

(Continued)
rate of precancerous lesions treatment were retrieved from meta-analysis and systematic reviews. Meanwhile, the remission rate of stage-specific invasive cervical cancer was calibrated based on estimates of the mortality related to cervical cancer in Lao PDR (Table 2).

Model calibration

The population was stratified by gender and age. The model is in the form of a realistic age structured (RAS) model. The equations were numerically solved in Berkeley Madonna version 8.3.18 [27]. The model was calibrated using maximum likelihood for the demographic distribution, the age-specific distribution of the 2014-estimated incidence of cervical cancer and mortality related to cervical cancer data in Lao PDR. The demographic distribution followed an exponential distribution using UN data to predict the changing birth and death rates over time for Lao PDR [28]. To calibrate the age-specific incidence of cervical cancer, we assumed that only the infection rate was different from the Kim et al. model [14]. We consequently calculated an infection rate multiplier to calibrate the incidence of cervical cancer according to the Globocan estimates.

The calibration of parameters for the age and stage-specific mortality rates of cervical cancer was conducted by varying the proportion of women receiving treatment for local, regional and distant cancer, the monthly death rates due to treatment complications and the age and stage-specific remission rates. The true proportion of women receiving a treatment in Lao PDR is unknown; we therefore estimated its value according to the experts’ opinion. The best guess of the proportion of women receiving a treatment for a local, regional or distant cancer was 100%, 80% and 70%, respectively.

Scenarios

Scenarios included the baseline option and the various prevention program options. The baseline option considered that no vaccination program existed and that, based on WHO estimates,
The coverage of a cytology screening program where screening was repeated every three years was 5.2% [1].

The scenarios were built on the following options: 1) girls vaccination alone, 2) girls vaccination combined with screening: either with VIA, rapid HPV DNA testing, combined VIA and conventional cytology testing, liquid-based cytology (LBC) or conventional cytology, and 3) screening alone. The combined VIA and conventional cytology is giving VIA and cytology

### Table 2. Summary of input other parameters for the model.

| Parameters                                             | Value (range)                      | Distribution | Source |
|--------------------------------------------------------|------------------------------------|--------------|--------|
| **VIA**                                               |                                    |              |        |
| Sensitivity (95% Confidence interval)                  | 73.2% (66.5–80.0%)                | Beta         | [16]   |
| Specificity (95% CI)                                  | 86.7% (82.9–90.4%)                | Beta         |        |
| **Conventional cervical cytology**                     |                                    |              |        |
| Sensitivity for CIN23                                  | 59% (29–82%)                      | Beta         | [17]   |
| Specificity                                            | 94% (88–99%)                      | Beta         |        |
| **ThinPrep Cervical cytology**                         |                                    |              |        |
| Sensitivity for CIN23                                  | 88% (70–94%)                      | Beta         | [17, 18]|
| Specificity                                            | 88% (65–97%)                      | Beta         | [19]   |
| **Combined testing VIA and conventional cytology**     |                                    |              |        |
| Sensitivity to detect high-grade CIN                   | 87% (83–90%)                      | Beta         | [20]   |
| Specificity                                            | 79% (63–89%)                      | Beta         |        |
| **Rapid HPV DNA testing**                              |                                    |              |        |
| Sensitivity to detect high-grade CIN                   | 81.5% (76.5–85.8%)                | Beta         | [21]   |
| Specificity                                            | 91.6% (81.8%-97.4%)               | Beta         |        |
| **Colposcopy**                                         |                                    |              |        |
| Sensitivity for high-grade CIN                         | 96% (64–99%)                      | Beta         |        |
| Sensitivity                                            | 48% (30–93%)                      | Beta         |        |
| Loss to follow-up per visit                            | 15% (0–50)                        | Beta         |        |
| **Probability of treatment for High grade CIN in Cervical cytology** | LEEP: 80% (50–80%) Hysterectomy: 20% (20–50%) | Beta         | Assumption ‡ |
| ≤ 35 years                                             |                                    |              |        |
| > 35 years                                             | Hysterectomy: 80% (50–80%)        | Beta         |        |
| **Proportion of recovery**                             |                                    |              |        |
| Cryotherapy                                            |                                    |              |        |
| Low-grade CIN                                          | 94% (85–95)                       | Beta         | [23]   |
| High-grade CIN                                         | 86% (83–89)                       | Beta         |        |
| LEEP: High-grade CIN                                   | 96.7% (90–98%)                    | Beta         | [24]   |
| Hysterectomy: Any CIN                                  | 99% (90–100%)                     | Beta         | [25]   |
| **Access to care**                                     |                                    |              |        |
| Local cervical cancer                                  | 80% (50–100)                      | Beta         | Assumption ‡ |
| Regional cervical cancer                               | 80% (0–50)                        | Beta         | Assumption ‡ |
| Distant cervical cancer                                | 80%                               | Beta         | Assumption ‡ |
| Vaccine efficacy against HPV type 16 and 18 infection   | 100%                              | Beta         | [26]   |

Note:
‡ Assumption was based on experts' opinion

Women with local cervical cancer are treated by hysterectomy
Women with regional cervical cancer are treated by chemoradiation
Women with distant cancer are given palliative care

doi:10.1371/journal.pone.0162915.0002
testing at the same time. The positivity is defined as either one positive. Screening strategies were selected based on feasibility and accessibility considerations relevant to the Lao context. Screening, VIA, cytology and HPV DNA testing, are done by a gynaecologist during gynaecological outpatient visits.

In each screening scenario, different initial ages for screening were considered: 20, 25 and 30 years old. The maximum age was fixed at 65 years. The initial age of screening was considered in three different group in comparison. Starting screening at 20 years of age is the recommendation for HPV DNA testing in USA [29], 30 years of age as a recommendation of WHO [30]. Moreover, the frequency of screening was fixed at either yearly, three-yearly or five-yearly intervals. Yearly interval screening reflects the current practice in Vientiane Capital. Three-yearly intervals follow WHO recommendations [30] and five-yearly intervals are current practice in the USA [29].

In all options, base-case analyses were performed with a screening coverage assumed to be 50% (range: 10%-80%). Lost to follow-up was assumed to be 15% per visit (range: 0%-50%). The proportion of women receiving cancer treatment among diagnosed patients was calibrated to the mortality rate of cervical cancer. The age- and stage-specific monthly remission rates for cancer treatment were calibrated based on the estimated mortality rates of cervical cancer (summary table in S1 Appendix) [1]. We assumed that the cytology alone option or combined with VIA is a three-visit approach. The first visit refers to primary screening; the second refers to receiving the results and making an appointment in case of a positive result. The third refers to colposcopy with direct biopsy. Meanwhile, rapid HPV DNA testing is a two-visit approach. The first visit refers to primary screening. The second refers to colposcopy with direct biopsy in case of a positive result. VIA is considered as a single-visit "see-and-treat approach".

The coverage of HPV vaccination in girls was assumed to be about 70% (30–80%), with 100% (30–100%) effectiveness against HPV types 16 and 18 and a lifelong protection (10 years to lifelong).

Costing

We considered a public health care system perspective for cost estimations. Only direct medical and programmatic costs were considered. Details on the approach used to calculate the consumption of items are described in the S1 Appendix. Briefly, we used data from the Ministry of Health (personal communication with Maytry Sanchanthixay, 2014) collected in central hospitals for a study aimed at determining costs per patient for each hospital. These data were used to estimate the screening visit and treatment cost. The cytology alone or combined with VIA options requires three visits. The first visit is for screening, the second for receiving the result and making an appointment for positive cases. The third is for a colposcopy with a direct biopsy. Meanwhile, rapid HPV DNA testing requires two visits. The first is for primary screening. The second refers to colposcopy with direct biopsy in the case of a positive result. VIA requires only one "see-and-treat approach" visit.

The cost of invasive cervical cancer treatment was retrieved from a study done in 72 GAVI-eligible countries [31]. The items of the screening programmatic cost included quality control, training, administration and recruitment costs.

The base case per dose cost of the vaccine was based on the purchasing cost from GAVI (4.5 I$ per dose) [32]. The full programmatic cost of the three-dose HPV vaccine per girl is 29.1 international dollars (I$) according to a previous survey on the pilot project of girl vaccination in Vientiane capital (Personal communication with Phannanyone Philakong, 2015). Unit prices are reported as 2013 international dollars, using the purchasing power parity (PPP) exchange rate (1 international dollar I$ = 2,694.27 Lao kip) [33]. To converse the local
currency to international dollars, tradable and non-tradable goods were separately converted (Table 3).

### Simulation analyses

The simulation process was run deterministically over a 100 year-span to capture the short and long term benefits of vaccination. For each option, the output consisted of the cumulative number of cervical cancers per 1,000 women, the DALYs per 1,000 women, and the cost of screening and treatment per 1,000 women. The strategies were ranked based on their cost, from the lowest to the highest. In the case of a non-dominant situation, strong or extended dominance, the incremental cost-effectiveness ratio was calculated using the reduction of cervical cancer cases and DALYs averted as denominators. DALYs were calculated based on the Global Burden of Disease without age weighting [34]. The disability weight for cancer treatment was retrieved from the current literature [35]. For each strategy, C/E was calculated using the reduction in the number of cervical cancer cases and DALYs averted as denominators.

All costs and DALYs were discounted at a rate of 3% in base case simulations to convert future costs and life expectancies and durations of disability to their present value [10]. However, other discount rates of 0% to 5% for DALYs and 6% for costs were also explored. The results were interpreted taking into account the recommendations of the UN Commission on Macroeconomics and Health which proposed classifying cost-effectiveness studies into three categories: 1) highly cost-effective (ICER < GDP per capita); 2) cost-effective (ICER between 1–3 times GDP per capita); and 3) not cost-effective (ICER > 3 times GDP per capita), based on the willingness-to-pay threshold recommended by the UN Commission on Macroeconomics and Health [36]. The GDP per capita in 2013 was about 4,822 international dollars using the Purchasing Power Parity (PPP) exchange rate [37].

---

**Table 3. Costing parameters.**

| Item                        | Unit price (International dollar) | Distribution | Source                                                                 |
|-----------------------------|-----------------------------------|--------------|------------------------------------------------------------------------|
| VIA ‡                       | 26.45                             | Gamma        | Personal communication with a head of department of health insurance.   |
| Conventional cervical cytology ‡ | 48.27                             | Gamma        | Ministry of health, Lao PDR                                            |
| Liquid-based (Thin-Prep) cervical cytology ‡ | 64.21                             | Gamma        |                                                                       |
| VIA + Conventional cervical cytology ‡ | 50.91                             | Gamma        |                                                                       |
| Rapid test of HPV DNA testing ‡ | 47.18                             | Gamma        |                                                                       |
| Colposcopy                  | 17.87                             | Gamma        |                                                                       |
| Cryotherapy                 | 23.59                             | Gamma        |                                                                       |
| LEEP                        | 120.40                            | Gamma        |                                                                       |
| Hysterectomy                | 1188.59                           | Gamma        |                                                                       |
| Treatment cost of Local cancer §§ | 745.57 (372.79–1491.15)           | Gamma        | [31]                                                                  |
| Treatment cost of regional cancer §§ | 845.68 (422.85–1691.36)          | Gamma        |                                                                       |
| Treatment cost of distant cancer §§ | 845.68 (422.85–1691.36)         | Gamma        |                                                                       |
| Vaccine cost per doses      | 4.5                               | Gamma        |                                                                       |
| Programmatic cost of vaccination for three doses | 29.1                               | Gamma        | Personal communication with Phanmanyson Philakong, WHO.                |

Note:

‡ Screening cost includes both direct medical cost and programmatic cost.

§§ Cost is unit price per person, 2013 International dollars exchange using purchasing power parity (PPP) exchange rate (1 I$ = 2,694.27 kips) [33] and the price of cancer treatment was adjusted from 2005 to 2014 using consumer price index (77.33 in 2005 and 122.52 in 2014) [11].

doi:10.1371/journal.pone.0162915.t003
Sensitivity analyses

One-way sensitivity analyses were conducted on the cost of the vaccine, screening and vaccination coverage, lost to follow-up, and sensitivity of VIA and conventional cytology, which were expected to significantly influence the incremental cost-effectiveness ratios.

In order to take into account uncertainties and joint effects, multi-way sensitivity analyses on parameters were conducted using a probabilistic sensitivity analysis. Each parameter was randomly drawn from its distribution (summary table in the S1 Appendix). As stated above, the parameters that were varied included: natural history progression of HPV infection, the proportion of people receiving treatment, monthly remission rates of precancerous lesions and cancer treatment, screening sensitivity and specificity, screening coverage, vaccine coverage, and vaccine-induced immunity, effectiveness of the vaccine, disability weight, and discount rate. The costing parameters, with the exception of cancer treatment, were varied by 75% in the sensitivity analyses (summary table in the S1 Appendix) by using gamma distributions. A lognormal distribution was used for the multipliers of the natural history of cervical cancer and a beta distribution for other parameters.

The Monte Carlo simulation was run for 1 000 iterations with Berkeley Madonna [27]. The program computes mean and standard deviations for each option. Acceptability curves were produced according to the probability of the ICERs to be cost-effective, taking into account the recommendation of the UN Commission on Macroeconomics and Health on various ceiling ratios. Acceptability curves were produced to take into account various willingness-to-pay thresholds as recommended by the UN Commission on Macroeconomics and Health [36]. The acceptability curve was based on the results of probabilistic sensitivity analyses [38].

Results

Impact of prevention strategies

The model output of demographic distribution showed that the virtual population was similar to the general population in terms of age distribution and trends over time. After the equilibrium state was reached, the age-specific incidence of cervical cancer and the mortality rate predicted were similar to expected values, and were consistent over the time span of the simulation (S1 Appendix).

In base-case analyses, the most effective strategy was a program consisting of annual VIA screening for 20–65 year old women in addition to a vaccination program for 10-year-old girls. This strategy was predicted to prevent 87% of cervical cancers and produce a gain of 50 DALYs per 1 000 women, about 32% less cancer and 11 additional averted DALYs per 1 000 women compared to a program consisting of only vaccination in girls. In the case that implementing a VIA program is not realistic, rapid HPV DNA testing in addition to a vaccination program was predicted to be the most effective option, with an 85.7% cancer reduction and 49.3 DALYs averted per 1 000 women. Among cytology-based screening strategies, LBC and combined VIA and cytology testing in addition to a vaccination program were predicted to be equally the most effective options, with an 84% cancer reduction and 49 DALYs averted per 1 000 women.

When we compared different initial ages for a screening program and frequencies of screening within the same screening strategy, we found that screening at an early age of 20 or 25 years old, added a slight reduction in the number of cancers compared to a program starting at the age of 30. The number of cancers was predicted to be further reduced when the frequency of the screening intervals was increased, i.e. screening with VIA for 30–65 year old women alone was shown to reduce the number of cancers by 44%, 58% and 80%, if screening was performed every five years, every three years or every year, respectively.
In terms of costs, LBC was predicted to be the most expensive option, followed by the combined VIA and cytology testing, rapid HPV DNA testing and VIA options, respectively (S1 Appendix).

Cost-effectiveness

Table 4 shows the comparison of all available screening strategies. In base-case scenarios, the girl vaccination only program was dominated by a program consisting of three-yearly VIA screening for 30–65 year old women. VIA screening also dominated other screening strategies. Therefore, comparisons were conducted only among VIA screening options. Two strategies, based on the GDP per capita threshold ratios, were predicted to be very cost-effective in terms of cancer reduction compared to the next best strategy: a program consisting of VIA screening for 30–65 year old women every five years alone, or an every-three-year program combined with vaccination. These cost 4 468 IS$ and 4 166 per case cancer reduction and 2 544 IS$ and 351 IS$ per DALY averted, respectively. In addition to these strategies, others were also predicted to be very cost-effective in terms of DALYs averted. These included a VIA screening program targeting 25–65 year old women every five years, a VIA screening program targeting 30–65 year old women every three years alone and a VIA screening program targeting 30–65 year old women every five years to which is added a girl vaccination component. These cost 856 IS$; 1 064 IS$; and 1 362 IS$ per DALYs averted, respectively.

If VIA alone is not realistic, rapid HPV DNA testing was predicted to be more cost-effective than cytology-based screening. Among these options, compared to the next best strategy, a screening program for 30–65 year old women every 3 and 5 years in addition to a girl vaccination component were predicted to be very cost-effective. They cost 4 391 and 2 102 IS$ per DALYs averted. An annual screening strategy was predicted to be cost-effective, costing 10 983 IS$ per DALYs averted.

If cytology and the combined VIA and conventional cytology testing strategies are realistic, the combined VIA with conventional cytology testing option was predicted to be more cost-effective than the cytology-based screening alone option. Among these, a program consisting of screening 30–65 year old women every five years was the most attractive option, costing 2 836 IS$ per DALY averted compared to a program consisting of only girl vaccination. Regarding the cytology-based screening options, we found that a girl vaccination program dominated screening alone options. LBC was predicted to be more cost-effective than conventional cytology. A program consisting of screening 30–65 year old women every five years in addition to a girl vaccination program was the most attractive option, costing 3 455 IS$ per DALY averted compared to the vaccination alone option. Also, the conventional cytology-based screening option using a five-year interval was predicted to be more cost-effective than using other frequency intervals (Table 5).

Sensitivity analyses

One-way sensitivity analyses showed that three-yearly VIA alone for women aged 30–65 years old is less effective than the HPV vaccination alone when its coverage is lower than 50% or when its sensitivity is 58.5% and lower. As a result, HPV vaccination alone becomes more cost-effective than the three-yearly VIA alone in this case. The on-way sensitivity analyses also showed that it was still more cost-effective to combine the screening strategy with vaccination than either component alone when the vaccination coverage was suboptimal. The same result was found when screening coverage was suboptimal, compared to vaccination alone. However, the combination of screening and vaccination was predicted to provide ICER higher than one GDP per capita when the cost of vaccine is higher than 50 IS$ per dose. Meanwhile, rapid HPV
Table 4. Cost-effectiveness of screening strategy alone combined with 10-years-old girl vaccination.

| Option | Total cost per 1000 women | Cancers per 1000 women | Cancer reduction (%) | DALYs averted per 1000 women | ICER (cancer reduction) | ICER (DALYs averted) |
|--------|---------------------------|------------------------|----------------------|-------------------------------|------------------------|---------------------|
| All screenings are realistic | | | | | | |
| Baseline | 4716 | 4.8 | Ref | Ref | - | - |
| Five-yearly VIA_30–65 | 13325 | 2.7 | 43.5 | 24.5 | 4166 | 351 |
| Five-yearly VIA_25–65 | 15598 | 2.5 | 47.7 | 27 | 11302 | 895 |
| Three-yearly VIA_30–65 | 21766 | 2 | 57.9 | 32.8 | 12771 | 1064 |
| Vaccination | 21824 | 2.1 | 54.9 | 30.7 | D | D |
| Five-yearly VIA_30–65 + vaccination | 30577 | 1.4 | 69.7 | 39.3 | 15718 | 1362 |
| Five-yearly VIA_25–65 + vaccination | 32862 | 1.4 | 70.5 | 39.8 | D | ED |
| Five-yearly VIA_20–65 + vaccination | 35202 | 1.4 | 71 | 40.2 | ED | ED |
| Three-yearly cytology_30–65 | 37199 | 3 | 36.6 | 21.8 | D | D |
| Three-yearly HPV testing_30–65 | 37242 | 2.2 | 53.5 | 31.8 | D | D |
| Three-yearly VIA_30–65 + vaccination | 39051 | 1.2 | 75.2 | 42.6 | 4468 | 2544 |
| Three-yearly VIA+cytology_30–65 | 41858 | 2.5 | 48.3 | 28.7 | D | D |
| Three-yearly VIA_25–65 + vaccination | 42862 | 1.1 | 76.1 | 43.2 | D | ED |
| Three-yearly VIA_20–65 + vaccination | 46763 | 1.1 | 76.7 | 43.6 | D | ED |
| Five-yearly HPV testing_20–65 + vaccination | 47694 | 1.4 | 69.6 | 40.2 | ED | ED |
| Three-yearly LBC_30–65 | 49868 | 2.4 | 48.6 | 28.9 | D | D |
| Three-yearly cytology_30–65 + vaccination | 54264 | 1.6 | 67.1 | 38.5 | D | D |
| Three-yearly HPV testing_30–65 + vaccination | 54327 | 1.3 | 73.5 | 42.6 | D | D |
| Three-yearly VIA+cytology_30–65 + vaccination | 58935 | 1.4 | 71.5 | 41.3 | D | D |
| Three-yearly HPV testing_25–65 + vaccination | 60775 | 1.2 | 74.4 | 43.1 | ED | ED |
| Yearly VIA_30–65 | 64261 | 1 | 79.9 | 45.7 | ED | ED |
| Three-yearly LBC_30–65 + vaccination | 66944 | 1.3 | 71.6 | 41.4 | D | D |
| Three-yearly HPV testing_20–65 + vaccination | 67411 | 1.2 | 75 | 43.5 | D | D |
| Yearly VIA_30–65 + vaccination | 81575 | 0.7 | 85.7 | 49 | 85116 | 6733 |
| Yearly VIA_25–65 + vaccination | 93002 | 0.6 | 86.5 | 49.4 | D | 24136 |
| Yearly VIA_20–65 + vaccination | 104683 | 0.6 | 87 | 49.8 | 422480 | 30462 |
| Yearly HPV testing_30–65 | 109208 | 1.1 | 77.5 | 45.7 | D | D |
| Yearly cytology_30–65 | 109312 | 1.6 | 66.5 | 39.3 | D | D |
| Yearly VIA+cytology_30–65 | 123124 | 1.2 | 74.5 | 44 | D | D |
| Yearly HPV testing_30–65 + vaccination | 126370 | 0.7 | 84.4 | 49.2 | D | D |
| Yearly cytology_30–65 + vaccination | 126424 | 1 | 78.8 | 45.8 | D | D |
| Yearly VIA+cytology_30–65 + vaccination | 140273 | 0.8 | 82.8 | 48.2 | D | D |

(Continued)
DNA testing became more attractive when the sensitivity of VIA was 30% less than the one in the base-case or when there was no loss to follow-up for rapid HPV DNA testing screening. LBC was not more cost-effective than conventional cytology if the sensitivity of conventional cytology was 70% or higher (S1 Appendix).

Multi-way sensitivity analyses did not change the rank of cost-effectiveness in base-case analyses. VIA screening remained dominant over other screening methods, but screening 30–65 year old women with VIA every year becomes more attractive than every three years, with an average cost of 4 202 I$ per DALY averted. Meanwhile, the ICER for a combined vaccination and VIA screening every three years was 1 567 I$ per DALY averted compared to screening every five years.

**Table 4. (Continued)**

| Option                              | Total cost per 1000 women | Cancers per 1000 women | Cancer reduction (%) | DALYs averted per 1000 women | ICER (cancer reduction) | ICER (DALYs averted) |
|-------------------------------------|---------------------------|------------------------|----------------------|-------------------------------|-------------------------|----------------------|
| Yearly HPV testing_25–65 + vaccination | 145701                    | 0.7                    | 85.1                 | 49.6                          | 567338                  | 42121                |
| Yearly LBC_30–65                    | 147137                    | 1.2                    | 74.7                 | 44.1                          | D                       | D                    |
| Yearly LBC_30–65 + vaccination      | 164287                    | 0.8                    | 82.9                 | 48.2                          | D                       | D                    |
| Yearly HPV testing_20–65 + vaccination | 165588                    | 0.7                    | 85.7                 | 49.6                          | D                       | D                    |

Note:
All screening strategies with different initial age “20, 25, and 30 years old” and screening interval “every year, and” were analyzed, but only some are presented here in this table. The detail is described in Appendix.
Baseline refers to no vaccination with 5.2% cytology screening for women aged 18–68 years old.
Vaccination is for 10-years-old girls. Cytology refers to conventional cervical cytology; LBC refers to liquid-based cervical cytology; HPV testing refers to rapid HPV DNA testing; VIA+cytology refers to the combined testing VIA and cytology.
The incremental cost of effectiveness ratio expressed as cancer prevented or DALY averted is listed in order of increasing cost. In non-dominant strategy, the ICER was calculated by devising different cost to different effectiveness.
**D** refers to strong dominance, which is expressed as higher cost, but lower effectiveness than alternative options.
**ED** refers to extendedly dominance, which has higher ICER than the next ICER.

**Discussion**
Four main findings can be deduced from our results: 1) the combined vaccination and screening option was predicted to be more cost-effective than either strategy alone; 2) screening 30–65 year old women with VIA every three years in addition to girl vaccination was the most attractive strategy; 3) excluding the VIA screening alone option, rapid HPV DNA testing in addition to a girl vaccination program was predicted to be the most attractive option, followed
Table 5. The incremental cost effectiveness ratio (ICER) of screening strategies and 10-year-old girl vaccination by realistic assumption.

| VIA alone is not realistic | ICER (cancer reduction) | ICER (DALY averted) | When cytology or combined with VIA is realistic | ICER (cancer reduction) | ICER (DALY averted) |
|---------------------------|------------------------|---------------------|-------------------------------------------------|------------------------|---------------------|
| Baseline                  | -                      | -                   | Baseline                                        | -                      | -                   |
| Vaccination               | 6555                   | 557                 | Vaccination                                     | 6555                   | 557                 |
| Five-yearly cytology_30–65| D                      | D                   | Five-yearly cytology_30–65                       | D                      | D                   |
| Five-yearly HPV testing_30–65| D                      | D                   | Five-yearly VIA+cytology_30–65                   | D                      | D                   |
| Five-yearly VIA+cytology_30–65| D                      | D                   | Five-yearly VIA+cytology_30–65                   | D                      | D                   |
| Five-yearly LBC_30–65     | D                      | D                   | Three-yearly cytology_30–65                      | D                      | D                   |
| Three-yearly cytology_30–65| D                      | D                   | Five-yearly cytology_30–65 + vaccination         | ED                     | ED                   |
| Three-yearly HPV testing_30–65| ED                    | ED                   | Three-yearly VIA+cystology_30–65                 | D                      | D                   |
| Five-yearly cytology_30–65 + vaccination | ED | ED | Five-yearly VIA+cystology_30–65 + vaccination | 38253 | 2836 |
| Five-yearly HPV testing_30–65 + vaccination | 28397 | 2102 | Five-yearly VIA+cystology_25–65 + vaccination | ED | ED |
| Three-yearly VIA+cytology_30–65| D                      | D                   | Five-yearly LBC_30–65 + vaccination              | D                      | D                   |
| Three-yearly cytology_30–65 + vaccination | D                      | D                   | Three-yearly VIA+cystology_30–65 + vaccination | 66830 | 5068 |
| Three-yearly HPV testing_30–65 + vaccination | 57639 | 4391 | Three-yearly VIA+cystology_30–65 + vaccination | ED | ED |
| Three-yearly VIA+cytology_30–65 + vaccination | D                      | D                   | Three-yearly LBC_30–65 + vaccination             | D                      | D                   |
| Three-yearly cytology_30–65 + vaccination | D                      | D                   | Three-yearly VIA+cystology_20–65 + vaccination | ED | ED |
| Yearly HPV testing_30–65  | ED                     | ED                   | Yearly cytology_30–65                            | D                      | D                   |
| Yearly cytology_30–65     | D                      | D                   | Yearly VIA+cystology_30–65                        | ED                     | ED                   |
| Yearly VIA+cystology_30–65| D                      | D                   | Yearly VIA+cystology_30–65 + vaccination          | ED                     | ED                   |
| Yearly HPV testing_30–65  | 139597                 | 10983               | Yearly VIA+cystology_30–65 + vaccination          | 151018                 | 11771               |
| Yearly cytology_30–65     | D                      | D                   | Yearly LBC_30–65                                | D                      | D                   |
| Yearly VIA+cystology_30–65| D                      | D                   | Yearly VIA+cystology_25–65 + vaccination          | 608081                 | 44987               |
| Yearly LBC_30–65 + vaccination | D                      | D                   | Yearly LBC_30–65 + vaccination                   | D                      | D                   |
| Yearly LBC_30–65 + vaccination | D                      | D                   | Yearly VIA+cystology_20–65 + vaccination          | 786975                 | 61537               |

**When only cytology is realistic**

| Baseline                  | -                      | -                   | Baseline                                        | -                      | -                   |
| Vaccination               | 6555                   | 557                 | Vaccination                                     | 6555                   | 557                 |
| Five-yearly cytology_30–65| D                      | D                   | Five-yearly cytology_30–65                       | D                      | D                   |
| Five-yearly LBC_30–65     | D                      | D                   | Five-yearly cytology_25–65                       | D                      | D                   |
| Three-yearly cytology_30–65| D                      | D                   | Five-yearly cytology_20–65                       | D                      | D                   |
| Five-yearly cytology_30–65 + vaccination | ED | ED | Three-yearly cytology_30–65 + vaccination | D                      | D                   |

(Continued)
by combined VIA and conventional cytology testing, the liquid-based cytology and conventional cytology option in addition to a girl vaccination program option, respectively; 4) the probability of cost-effectiveness was around 60–67% for screening strategies.

In base-case analyses, the option three-yearly VIA screening for women aged 30–65 years old dominated the girl HPV vaccination alone option. Our findings are different from what has been shown by others. This might be explained by the fact that most studies have been conducted in developed countries where VIA screening was not considered. As found in our study, rapid HPV DNA testing and cytology alone are less effective than HPV vaccination. Furthermore, among studies that included the VIA screening option, different strategies such as VIA screening once or five times in a lifetime and a lower screening coverage were considered [39]. Moreover, Praditsitthikorn and colleagues [40] assumed 20% screening coverage. In our study, once the screening coverage is less than 50% or the sensitivity of VIA is equal or less than 58.5%, the HPV vaccination option becomes more cost-effective.

Table 5. (Continued)

| VIA alone is not realistic | ICER (cancer reduction) | ICER (DALY averted) | When cytology or combined with VIA is realistic | ICER (cancer reduction) | ICER (DALY averted) |
|---------------------------|-------------------------|---------------------|-----------------------------------------------|-------------------------|---------------------|
| Five-yearly LBC_30–65 + vaccination | 46610 | 3455 | Five-yearly cytology_30–65 + vaccination | 49716 | 3709 |
| Three-yearly LBC_30–65 | D | D | Three-yearly cytology_25–65 | D | D |
| Five-yearly LBC_25–65 + vaccination | D | ED | Five-yearly cytology_25–65 + vaccination | D | ED |
| Three-yearly cytology_30–65 + vaccination | D | D | Five-yearly cytology_20–65 + vaccination | D | ED |
| Five-yearly LBC_20–65 + vaccination | D | ED | Three-yearly cytology_20–65 | D | D |
| Three-yearly LBC_30–65 + vaccination | 79743 | 6048 | Three-yearly cytology_30–65 + vaccination | 66648 | 5017 |
| Three-yearly LBC_25–65 + vaccination | D | D | Three-yearly cytology_25–65 + vaccination | D | ED |
| Three-yearly LBC_20–65 + vaccination | ED | ED | Three-yearly cytology_20–65 + vaccination | ED | ED |
| Yearly cytology_30–65 | D | D | Yearly cytology_30–65 | D | D |
| Yearly cytology_30–65 + vaccination | 172755 | 13544 | Yearly cytology_30–65 + vaccination | 128937 | 9888 |
| Yearly LBC_30–65 | D | D | Yearly cytology_25–65 | D | D |
| Yearly LBC_30–65 + vaccination | 196119 | 15155 | Yearly cytology_25–65 + vaccination | 490402 | 35960 |
| Yearly LBC_20–65 + vaccination | 730436 | 54053 | Yearly cytology_20–65 | D | D |
| Yearly LBC_20–65 | 6611733 | 73818 | Yearly cytology_20–65 + vaccination | D | 51006 |

Note:
All screening strategies with different initial age “20, 25, and 30 years old” and screening interval “every year, and” were analysed, but only some are presented here in this table.
Baseline refers to no vaccination with 5.2% cytology screening for women aged 18–68 years old.
Vaccination is for 10-years-old girls. Cytology refers to conventional cervical cytology; LBC refers to liquid-based cervical cytology; HPV testing refers to rapid HPV DNA testing; VIA+cytology refers to the combined testing VIA and cytology.
The incremental cost of effectiveness ratio expressed as cancer prevented or DALY averted is listed in order of increasing cost. In non-dominant strategy, the ICER was calculated by devising different cost to different effectiveness.
D refers to strong dominance, which is expressed as higher cost, but lower effectiveness than alternative options.
ED refers to extendedly dominance, which has higher ICER than the next ICER.

doi:10.1371/journal.pone.0162915.t005
Among screening strategies, VIA screening was predicted to be the most attractive option. This result is similar to that of other studies conducted in developing countries [40–42]. This might be explained by the combination of its advantages. First, VIA screening has higher sensitivity, in base case scenarios, than a conventional cervical cytology option and only slightly lower than other screening options considered in this study. Second, VIA can be used as a single-visit approach; subsequently there is no loss to follow-up among positive cases that require treatment. Third, although cryotherapy, the treatment for VIA positive patients, who may have either low-grade or high-grade precancerous lesions, has a slightly higher recurrence rate [23] compared to the loop electrosurgical excision procedure (LEEP), the difference is so small that it would not be expected to impact the overall effectiveness of treatment for precancerous lesions. Nevertheless, VIA is controversial due to its limitations; a positive VIA does not always reflect precancerous or cancerous lesions. Furthermore, invasive cervical cancer cases might not be adequately treated on the basis of a VIA result alone [43]. VIA has a low positive predictive value, which could lead to unnecessary treatment and psychological repercussions [6, 44]. A positive VIA result can be due to polyps, inflammatory conditions, or squamous metaplasia [45]. Also, VIA is subjective. Its interpretation requires careful training and supervision. It is also not appropriate for postmenopausal women because lesions may occur within the...
endocervical canal, which cannot be visualized. That is why WHO recommends using VIA only for women who are less than 50 years old [46].

As demonstrated in the sensitivity analyses, the VIA screening option with a 30% suboptimal sensitivity was not cost-effective compared to the rapid HPV DNA testing options. In the case where VIA is not realistic, rapid HPV DNA testing becomes the most attractive option. The dominance of the rapid HPV DNA testing option over the cytology-based screening option was also reported in China [47]. The use of HPV DNA testing needs to take into consideration its benefits and disadvantages. The advantage of HPV DNA testing is its high sensitivity and specificity, its reproducibility and the fact that the sample can be collected by the patients [46]. However, the test requires appropriate storage and accessibility. Moreover, a positive case does not necessarily mean an abnormal cervix or a cervical cancer, and does not automatically require treatment. The infection mostly regresses spontaneously within 1–2 years and induces acquired immunity with an estimated duration of at least 10 years [48, 49]. Also, a psychological burden has been reported among HPV-positive women [50].

With cytology-based screening, cervical cancer incidence could be reduced by 80% [51] if the sensitivity of cytology and screening coverage are high. LBC has a higher sensitivity than conventional cytology, but its cost is relatively higher [46]. Compared to VIA and rapid HPV DNA testing, a cytology-based screening option is more costly and less effective as a result of lower sensitivity and specificity [17]. Only 55% of true positive cases receive treatment. In this case, the combined VIA and conventional cytology testing option becomes attractive. The use of both tests as primary screening options might improve the detection of precancerous cases in spite of the large number of false positive cases, which leads to a higher rate of colposcopies and biopsies.

Maintaining a high sensitivity implies high programmatic cost both for the VIA and cytology approaches, because of the need of substantial quality control and training [52]. Compared to programmatic cost of cytology, the cost of VIA might consume less resources because it allows large-scale screening. The large-scale screening would reduce the cost of administration and recruitment, which accounts for 25% of the medical direct costs. However, the programmatic cost of VIA might be higher than the cost of rapid HPV DNA testing as the later one requires less resources for quality control and training [52]. Moreover, self-sampling method that could be done with the rapid HPV DNA testing would reduce the cost of screening and increase and maintain the screening coverage [52]. Nonetheless, further studies are desirable to provide more information on this issue.

Decisions regarding a national screening strategy must take into consideration both the advantages and limitations stated above. This could be summarized in terms of affordability, feasibility, accessibility and acceptability. There is therefore a need to further step-up the analyses of these factors in the Lao context prior to making a decision about which option to propose.

**Limitations**

Our model has several limitations: it assumes that the natural progression and regression of the cervix state do not depend on the setting. This assumption might under or overestimate progression and regression rates due to the fact that the epidemiological burden of disease is considerably different between countries. Subsequently, this might under or overestimate the cost of precancerous lesion treatment. However, because of the lack of available data on variables such as HPV prevalence, prevalence of CIN and HPV type distribution for lesions and cervical cancers, defining these parameters in the calibration process is difficult. We addressed this problem by conducting probabilistic sensitivity analyses, using the range of values found in the literature.
To simplify model assumptions, we had to assume that only women with high-grade CIN were treated despite the fact that women with low-grade CIN were followed-up every three to six months and were treated if the result remained positive on their second or third test. This might underestimate the cost of screening and treatment as well as the effect of cervical cytology and rapid HPV testing. However, to the best of our knowledge, this should not greatly impact the effectiveness or the total cost because some of the positive low-grade CIN cases will be lost to follow-up, and the cost of treatment of precancerous lesions for positive cases is marginal compared to screening costs.

Our study assumed that all women participated equally in the screening program even in subsequent screenings. This might overestimate screening coverage that could change over time among screened and unscreened women. Screened women with normal test results might not return to the next cycle and vice-versa.

The sensitivities and specificities used in our model were derived from the meta-analysis of available articles worldwide. However, both VIA and cytology-based screening approaches are subjective, and could vary across settings [46]. Future evidence on test performance relevant to the local context might better guide the decision-making processes.

We ignored some costs related to screening and precancerous lesion treatment. These include the cost of specimen delivery and the cost of complications following a treatment. This might underestimate the total cost per person. However, according to Goldhaber-Fiebert [53], these cost components are small relative to the cost of administration and equipment. Therefore, this is unlikely to have a big impact on ICER and should not bias our conclusions. Nevertheless, we based the cost of cancer treatment on Goldie and colleagues [31], which estimated these costs from data coming from other developing countries with similar economic level. Also, we assumed that some invasive cervical cancer cases did not access to treatment. This might underestimate the cost of the baseline scenario. Further investigation on this issue are desirable.

**Conclusions**

The combination of vaccination of preadolescent girls and screening was predicted to be more cost-effective than either component alone. Besides VIA, the rapid HPV DNA testing option was predicted to be more cost-effective than a cytology-based screening option or its combination with VIA. Therefore, in addition to girl HPV vaccination program, VIA or rapid HPV DNA should be considered for primary screening of precancerous lesions in Lao PDR.

**Supporting Information**

S1 Appendix. Detail of methodology and additional results. (DOCX)

**Acknowledgments**

We would like to thank the Mathematical and Economic Modelling group in Bangkok and those at Laval University for their contribution to the analysis and training. This includes Ben Cooper, Yoel Lubell, Wirichada Pan-ngum, Diane Fournier, Julie Duplantie and Léon Nshimyumukiza. We would also like to thank the Department of Health Insurance for providing the cost data related to health care expenditure in Vientiane hospitals. We also thank Dr. Alongkone Phengsavanh and Dr. Phetsamone Aroundlangsy for their advice on current practice relating to clinical and laboratory cervical cancer screening in Lao PDR.
Author Contributions
Conceptualization: PC DR LJW.
Formal analysis: PC LJW.
Funding acquisition: PC LJW.
Investigation: PC.
Methodology: PC DR.
Resources: PC DR MM KP.
Software: PC LJW.
Supervision: DR LJW LM.
Validation: PC DEM KP.
Visualization: PC DEM LM.
Writing – original draft: PC.
Writing – review & editing: DR LJW DEM KP LM MM.

References
1. Bruni L, Barrionuevo-Rosas L, Serrano B, Brotons M, Cosano R, Munoz J, et al. Human Papillomavirus and Related Diseases in Laos. Summary Report 2014-03-17. ICO Information Centre on HPV and Cancer (HPV Information Centre). 2014. Available: http://www.hpvcentre.net/statistics/reports/LAO.pdf. Accessed: 09 February 2015.
2. Kim JJ, Brissinon M, Edmunds WJ, Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine. 2008; 26 Suppl 10:K76–86. doi:10.1016/j.vaccine.2008.06.009 PMID: 18847560
3. Shelbaya SG, Saslow D. A Comprehensive Approach to Cervical Cancer: Improving Impact Today. In: Cain J, Shelbaya SG, editors. Global Guidance For Cervical Cancer Prevention and Control: International Federation of Gynecology and Obstetrics; 2009. p. 11–4.
4. IARC Working Group on evaluation of cervical cancer screening programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. British medical journal (Clinical research ed). 1986; 293(6548):659–64.
5. Bingham A, Bishop A, Coffey P, Winkler J, Bradley J, Dzuba I, et al. Factors affecting utilization of cervical cancer prevention services in low-resource settings. Salud publica de Mexico. 2003; 45 Suppl 3: S408–16. PMID:14746034
6. Srithipukho P, Thaweekul Y. Accuracy of visual inspection with acetic acid (VIA) for cervical cancer screening: a systematic review. Journal of the Medical Association of Thailand = Chotmaihet thamphaet. 2010; 93 Suppl 7:S254–61. PMID: 21294423
7. Gravitt PE, Coutlee F, Iftner T, Sellors JW, Quint WG, Wheeler CM. New technologies in cervical cancer screening. Vaccine. 2008; 26 Suppl 10:K42–52. doi: 10.1016/j.vaccine.2008.05.002 PMID: 18847556
8. Gage JC, Ajenifuja KO, Wentzensen N, Adepi AC, Stoler M, Eder PS, et al. Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. International Journal of Cancer International du cancer. 2012; 131(12):2903–9. doi: 10.1002/ijc.27563 PMID: 22473652
9. Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. The lancet oncology. 2008; 9(10):929–36. doi: 10.1016/S1470-2045(08)70210-9 PMID: 18805733
10. Adam T, Baltussen R, Tan Torres T, Evans D, Hutubessy R, Acharya A, et al. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva: World Health Organization. 2003. Available: http://www.who.int/choice/publications/p_2003_generalised_cea.pdf. Accessed 2013 Feb 3.
11. Welcome to Lao Statistics Bureau. Vientiane Capital. Available: http://www.nsc.gov.la/index.php?lang=en. Accessed 2014 Oct 16.
12. WHO (2012) Health Service Delivery Profile: Lao PDR 2012. Available: http://www.wpro.who.int/health_services/service_delivery_profile_laoprd.pdf. Accessed 2014 May 21.

13. Nation United. Lao People's Democratic Republic. Available: http://data.un.org/CountryProfile.aspx?crName=Lao%20People's%20Democratic%20Republic. Accessed 2013 Nov 19.

14. Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, et al. Multiparameter calibration of a natural history model of cervical cancer. American journal of epidemiology. 2007; 166(2):137–50. PMID: 17526866

15. Life tables for WHO Member States. World Health Organization. Available: http://apps.who.int/gho/data/node.imr.LIFE_0000000029?lang=en. Accessed 2014 Aug 24.

16. Qiao L, Li B, Long M, Wang X, Wang A, Zhang G. Accuracy of visual inspection with acetic acid and with Lugol's iodine for cervical cancer screening: Meta-analysis. The journal of obstetrics and gynaecology research. 2015.

17. Chen C, Yang Z, Li Z, Li L. Accuracy of several cervical screening strategies for early detection of cervical cancer: a meta-analysis. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2012; 22(6):908–21.

18. Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Annals of internal medicine. 2011; 155(10):687–97, W214–5. doi: 10.7326/0003-4819-155-1020111150-00376 PMID: 22006930

19. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstetrics and gynecology. 2008; 111(1):167–77. doi: 10.1097/01.AOG.0000269448.85807.b3 PMID: 18165406

20. Chanthavilay P, Mayxay M, Phongsavan K, Marsden DE, White LJ, Moore L, et al. Accuracy of Combined Visual Inspection with Acetic Acid and Cervical Cytology Testing as a Primary Screening Tool for Cervical Cancer: a Systematic Review and Meta-Analysis. Asian Pacific journal of cancer prevention: APJCP. 2015; 16(14):5899–90. PMID: 26320468

21. Jeronimo J, Bansil P, Lim J, Peck R, Paul P, Amador JJ, et al. A Multicountry Evaluation of careHPV Testing, Visual Inspection With Acetic Acid, and Papanicolaou Testing for the Detection of Cervical Cancer. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2014; 24(3):576–85.

22. Mitchell MF, Schottenfeld D, Tortolero-Luna G, Cantor SB, Richards-Kortum R. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstetrics and gynecology. 1998; 91(4):626–31. PMID: 9540955

23. Sauvaget C, Muwonge R, Sankaranarayanan R. Meta-analysis of the effectiveness of cryotherapy in the treatment of cervical intraepithelial neoplasia. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2013; 120(3):218–23.

24. Suprasert P, Panyaraj W, Kietpeerakool C. Recurrent rates with cervical intraepithelial neoplasia having a negative surgical margin after the loop electrosurgical excision procedure in Thailand. Asian Pacific journal of cancer prevention: APJCP. 2009; 10(4):587–90. PMID: 19827874

25. Jones HW III. Cone biopsy and hysterectomy in the management of cervical intraepithelial neoplasia. Bailliere's clinical obstetrics and gynaecology. 1995; 9(1):221–36. PMID: 7600728

26. Bosch FX. Human papillomavirus: science and technologies for the elimination of cervical cancer. Expert opinion on pharmacotherapy. 2011; 12(14):2189–204. doi: 10.1517/14656566.2011.956527 PMID: 21756205

27. Macey R, George O, Zahnley T. Berkeley Madonna (Version 8.3.18). University of California; 2010. Available: http://www.berkeleymadonna.com/download.html. Accessed 2013 Jun 19.

28. World Population Prospects: The 2012 Revision, DVD Edition. 2013. Available: http://esa.un.org/unpd/wpp/Excel-Data/population.htm. Accessed 2013 Aug 15.

29. ACOG Practice Bulletin Number 131: Screening for cervical cancer. Obstetrics and gynecology. 2012; 120(5):1222–38. Epub 2012/10/24. doi: 10.1097/AOG.0b013e318277c92a PMID: 23090560

30. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. World Health Organization 2013. Available: http://www.who.int/reproductivehealth/publications/cancers/screening_and_treatment_of_precancerous_lesions/en/.

31. Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine. 2008; 26(32):4080–93. doi: 10.1016/j.vaccine.2008.04.053 PMID: 18550229

32. Human papillomavirus vaccine support. Available: Global Alliance for Vaccines and Immunization (GAVI). Available: http://www.gavi.org/support/nvs/human-papillomavirus/. Accessed 2014 Apr 13.
33. PPP conversion factor GDP (LCU per international $): World Development Indicators. World Bank, International Comparison Program database. Available: http://data.worldbank.org/indicator/PA.NUS.PPP. Accessed 2015 Mar 17.

34. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2197–223. doi: 10.1016/S0140-6736(12)61689-4 PMID: 23245608

35. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2129–43. doi: 10.1016/S0140-6736(12)61680-8 PMID: 23245605

36. WHO Commission on Macroeconomics and Health. Macroeconomics and health: Investing in health for economic development. In: Steele H, editor. Report of the Commission on Macroeconomics and Health. Geneva, Switzerland. Available: http://whqlibdoc.who.int/publications/2001/924154550x.pdf. Accessed 2014 Jun 7.

37. Bank World. GDP per capita, PPP (current international $): World Development Indicators. World Bank, International Comparison Program database. Available: http://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD/countries?display=default. Accessed 2015 Mar 17.

38. Briggs AH, Weinstein MC, Fenwick EA, Ramon J, Sculptor MJ, Pattie AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Medical decision making: an international journal of the Society for Medical Decision Making. 2012; 32(5):722–32.

39. Sharma M, Orthejali J, van der Ham E, Sy S, Kim JJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand. BJOG: an international journal of obstetrics and gynaecology. 2012; 119(2):166–76.

40. Praditsitthikorn N, Teerawattananon Y, Tantivess S, Limwattananon S, Riewpaiboon A, Chichareon S, et al. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. PharmacoEconomics. 2011; 29(9):781–806. doi: 10.2165/11586560-000000000-00000 PMID: 21838332

41. Guerrero AM, Genuino AJ, Santillan M, Praditsitthikorn N, Chantarastapornchit V, Teerawattananon Y, et al. A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines. BMC public health. 2015; 15:730. doi: 10.1186/s12889-015-2046-1 PMID: 26223975

42. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahe C, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. The New England journal of medicine. 2005; 353(20):2158–68. PMID: 16291985

43. Sherris J, Wittet S, Klein A, Sellors J, Luciani S, Sankaranarayanan R, et al. Evidence-based, alternative cervical cancer screening approaches in low-resource settings. International perspectives on sexual and reproductive health. 2009; 35(3):147–54. doi: 10.1363/ifpp.35.147.09 PMID: 19805020

44. Sauvaget C, Fayette JM, Muwonge R, Wesley R, Sankaranarayanan R. Accuracy of visual inspection with acetic acid for cervical cancer screening. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2011; 113(1):14–24.

45. Sankaranarayanan R, Wesley R, Thara S, Dhakad N, Chandrakala B, Sebastian P, et al. Test characteristics of visual inspection with 4% acetic acid (VIA) and Lugol's iodine (VILI) in cervical cancer screening in Kerala, India. International journal of cancer Journal international du cancer. 2003; 106 (3):404–8. PMID: 12845681

46. WHO (2014) Comprehensive cervical cancer control: a guide to essential practice– 2nd ed. Available: http://apps.who.int/iris/bitstream/10665/144785/1/9789241548953_eng.pdf. Accessed 2014 Nov 09.

47. Levin CE, Sellors J, Shi JF, Ma L, Qiao YL, Orthejali J, et al. Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. International journal of cancer Journal international du cancer. 2010; 127(6):1404–11. doi: 10.1002/ijc.25150 PMID: 20049838

48. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005; 337(1):76–84. PMID: 15914222

49. Insinga RP, Dasbach EJ, Elbashar EH. Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC infectious diseases. 2009; 9:119. doi: 10.1186/1471-2334-9-119 PMID: 19640281

50. Wang KL, Jeng CJ, Yang YC, Chen CA, Cheng WF, Chen TC, et al. The psychological impact of illness among women experiencing human papillomavirus-related illness or screening interventions. Journal
of psychosomatic obstetrics and gynaecology. 2010; 31(1):16–23. doi: 10.3109/01674820903564440 PMID: 20121461

51. Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bulletin of the World Health Organization. 2001; 79(10):954–62. Epub 2001/11/06. PMID: 11693978; PubMed Central PMCID: PMCPMC2566667.

52. Shi JF, Chen JF, Canfell K, Feng XX, Ma JF, Zhang YZ, et al. Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: a micro-costing study. BMC health services research. 2012; 12:123. doi: 10.1186/1472-6963-12-123 PMID: 22624619

53. Goldhaber-Fiebert JD, Goldie SJ. Estimating the cost of cervical cancer screening in five developing countries. Cost effectiveness and resource allocation: C/E. 2006; 4:13. PMID: 16887041